Related references
Note: Only part of the references are listed.CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Mary E. Klein et al.
CANCER CELL (2018)
Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies
Dorota Kwapisz
BREAST CANCER (2018)
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Anand Mayakonda et al.
GENOME RESEARCH (2018)
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
A. Dispenzieri et al.
LEUKEMIA (2017)
The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma
Seweryn Mroczek et al.
NATURE COMMUNICATIONS (2017)
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
S. S. Chavan et al.
BLOOD CANCER JOURNAL (2017)
p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell
B. Tessoulin et al.
BLOOD REVIEWS (2017)
How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
Pieter Sonneveld et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma
Hans C. Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Compendium of FAM46C gene mutations in plasma cell dyscrasias
Marzia Barbieri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold et al.
BLOOD (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
Charlotte Pawlyn et al.
CLINICAL CANCER RESEARCH (2016)
ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization
Guangchuang Yu et al.
MOLECULAR BIOSYSTEMS (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
N. Bolli et al.
BLOOD CANCER JOURNAL (2016)
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an italian cohort study and overview of the literature
Marta Lionetti et al.
ONCOTARGET (2016)
A Simple Flow Cytometry-Based Barcode for Routine Authentication of Multiple Myeloma and Mantle Cell Lymphoma Cell Lines
Sophie Maiga et al.
CYTOMETRY PART A (2015)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
Ruben Niesvizky et al.
LEUKEMIA & LYMPHOMA (2015)
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
J. D. Leverson et al.
CELL DEATH & DISEASE (2015)
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Moritz Gerstung et al.
NATURE COMMUNICATIONS (2015)
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
Marta Lionetti et al.
ONCOTARGET (2015)
Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
Charlotte Kervoelen et al.
ONCOTARGET (2015)
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns
Ingrid Cifola et al.
ONCOTARGET (2015)
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Benoit Tessoulin et al.
BLOOD (2014)
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway
Sylvanie Surget et al.
BMC CANCER (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other
Sylvanie Surget et al.
LEUKEMIA & LYMPHOMA (2014)
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
Zhi-Fu Tao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
A high-performance computing toolset for relatedness and principal component analysis of SNP data
Xiuwen Zheng et al.
BIOINFORMATICS (2012)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
Sylvanie Surget et al.
CANCER RESEARCH (2012)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
ABT-737 is highly effective against molecular subgroups of multiple myeloma
Linda Bodet et al.
BLOOD (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
Jerome Moreaux et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
A diverse range of gene products are effectors of the type I interferon antiviral response
John W. Schoggins et al.
NATURE (2011)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Share Paper
